Intratubular malignant germ cells

A non-invasive lesion of the testis, characterized by the presence of malignant large germ cells with abundant cytoplasm in the seminiferous tubules. It may be associated with undescended or atrophic testis and infertility. The vast majority of cases progress to invasive germ cell tumors.


Testicular Cancer by AJCC v6 and v7 Stage

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:ThingWithTaxon

A term that refers to the staging of testicular cancer according to the American Joint Committee on Cancer, 6th and 7th editions.


Stage IB Testicular Cancer AJCC v6 and v7

Stage IB includes: (pT2, N0, M0, S0); (pT3, N0, M0, S0); (pT4, N0, M0, S0).  pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis.  pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion.  pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)


Stage IIB Testicular Cancer AJCC v6 and v7

Stage IIB includes: (Any pT/TX, N2, M0, S0); (Any pT/TX, N2, M0, S1).  pTX: Primary tumor cannot be assessed.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)


Stage I Testicular Non-Seminomatous Germ Cell Tumor AJCC v6 and v7

Stage I includes: pT1-4, N0, M0, SX.  pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis.  pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis.  pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion.  pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  SX: Marker studies not available or not performed. (AJCC 6th and 7th eds.)


Stage IA Testicular Cancer AJCC v6 and v7

Stage IA includes: pT1, N0, M0, S0.  pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)


Stage IIIB Testicular Cancer AJCC v6 and v7

Stage IIIB includes: (Any pT/TX, N1-3, M0, S2); (Any pT/TX, Any N, M1a, S2).  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. M1a: Non-regional nodal or pulmonary metastasis. S2: LDH 1.5-10 x N (N indicates the upper limit of normal for the LDH assay) or hCG 5,000-50,000 or AFP 1,000-10,000.  (AJCC 6th and 7th eds.)


Stage IIA Testicular Cancer AJCC v6 and v7

Stage IIA includes: (Any pT/TX, N1, M0, S0); (Any pT/TX, N1, M0, S1).  pTX: Primary tumor cannot be assessed.  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000. (AJCC 6th and 7th eds.)


Intratubular Seminoma

Intratubular germ cell neoplasia characterized by the complete filling of the seminiferous tubules by seminoma cells.


Stage IIIC Testicular Cancer AJCC v6 and v7

Stage IIIC includes: (Any pT/TX, N1-3, M0, S3); (Any pT/TX, Any N, M1a, S3); (Any pT/TX, Any N, M1b, Any S).  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. M1a: Non-regional nodal or pulmonary metastasis.  M1b: Distant metastasis other than to non-regional lymph nodes and lung.  S3: LDH more than 10 x N (N indicates the upper limit of normal for the LDH assay) or hCG more than 50,000 or AFP more than 10,000. (AJCC 6th and 7th eds.)


Testicular germ cell tumor mixed stage III

Stage III includes: Any pT/TX, Any N, M1, SX.  M1: Distant metastasis. SX: Marker studies not available or not performed.  (AJCC 6th and 7th eds.)


Stage II Testicular Seminoma AJCC v6 and v7

Stage II includes: Any pT/TX, N1-3, M0, SX.  pTX: Primary tumor cannot be assessed.  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. SX: Marker studies not available or not performed.  (AJCC 6th and 7th eds.)


Stage IIC Testicular Cancer AJCC v6 and v7

Stage IIC includes: (Any pT/TX, N3, M0, S0); (Any pT/TX, N3, M0, S1).  pTX: Primary tumor cannot be assessed.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)


Stage III Testicular Cancer AJCC v6 and v7


Stage III Testicular Seminoma AJCC v6 and v7


Stage 0 Testicular Cancer AJCC v6 and v7

Stage 0 includes: pTis, N0, M0, S0.  pTis: Intratubular germ cell neoplasia (carcinoma in situ).  N0: regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)


Stage I Testicular Cancer AJCC v6 and v7


Stage IS Testicular Cancer AJCC v6 and v7

Stage IS includes: Any pT/TX, N0, M0, S1-3.  pTX: Primary tumor cannot be assessed.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  S2: LDH 1.5-10 x N or hCG 5,000-50,000 or AFP 1,000-10,000.  S3: LDH more than 10 x N or hCG more than 50,000 or AFP more than 10,000. (AJCC 6th and 7th eds.)


Intratubular Embryonal Carcinoma

Intratubular germ cell neoplasia characterized by the filling of the seminiferous tubules by embryonal carcinoma cells. Central necrosis and calcifications are often present.


Testicular germ cell tumor mixed stage I


Stage II Testicular Cancer AJCC v6 and v7


Stage IIIA Testicular Cancer AJCC v6 and v7

Stage IIIA includes: (Any pT/TX, Any N, M1a, S0); (Any pT/TX, Any N, M1a, S1).  M1a: Non-regional nodal or pulmonary metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)


Stage II Testicular Non-Seminomatous Germ Cell Tumor AJCC v6 and v7


Testicular embryonal carcinoma stage III


Testicular germ cell tumor mixed stage II


Stage III Testicular Non-Seminomatous Germ Cell Tumor AJCC v6 and v7


fucosidosis

Fucosidosis is an extremely rare lysosomal storage disorder characterized by a highly variable phenotype with common manifestations including neurologic deterioration, coarse facial features, growth retardation, and recurrent sinopulmonary infections, as well as seizures, visceromegaly, angiokeratoma and dysostosis.


myosin XVI complex

biolink:CellularComponent biolink:AnatomicalEntity biolink:OrganismalEntity biolink:BiologicalEntity biolink:NamedThing biolink:PhysicalEssence biolink:SubjectOfInvestigation biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

A myosin complex containing a class XVI myosin heavy chains and associated light chains; myosin XVI heavy chains contain ankyrin repeat.


modulation by virus of host protein transport

biolink:BiologicalProcess biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:Occurrent biolink:OntologyClass biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

Any viral process that modulates the frequency, rate or extent of protein transport in its host organism.


Bone Hibernoma

A benign neoplasm that is composed of brown adipocytes and arises within or on the surface of bone.


negative regulation of isoprene biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of isoprene biosynthetic process.


regulation of isoprene biosynthetic process

Any process that modulates the frequency, rate or extent of isoprene biosynthetic process.


positive regulation of isoprene biosynthetic process

Any process that activates or increases the frequency, rate or extent of isoprene biosynthetic process.


salicylic acid catabolic process

The chemical reactions and pathways resulting in the breakdown of salicylic acid (2-hydroxybenzoic acid), a derivative of benzoic acid.


Human Papillomavirus-Related Head and Neck Squamous Cell Carcinoma of Unknown Primary

A squamous cell carcinoma associated with human papillomavirus that has metastasized to the head and neck region from an unknown primary anatomic site.


superoxide-generating NADPH oxidase activity

biolink:MolecularActivity biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:Occurrent biolink:OntologyClass biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

Catalysis of the reaction: NADPH + 2 O2 = H+ + NADP+ + 2 superoxide.


NADH oxidase H202-forming activity

Catalysis of the reaction: NADH + H+ + O2 = NAD + hydrogen peroxide (H2O2).


NADPH oxidase H202-forming activity

Catalysis of the reaction: NADPH + H+ + O2 = NADP + hydrogen peroxide (H2O2).


superoxide-generating NADH oxidase activity

Catalysis of the reaction: NADH + 2 O2 = H+ + NAD+ + 2 superoxide.


Inappropriate Sinus Tachycardia Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

Inappropriate sinus tachycardia at rest with heart rate  greater than 100 bpm that cannot be explained by any identifiable cause, including anemia, hypoxia, hypotension, or fever that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


Deep Tendon Reflex

biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:ThingWithTaxon

Contraction of a muscle triggered by a signal from a muscle spindle in response to a stimulus applied to a specific trigger point on the body. The strength of the response can provide insight into central and peripheral nerve performance.


Catalysis of the reaction: 2 H+[side 1] + 2 oxidized plastocyanin + plastoquinol-1 = 2 H+[side 2] + 2 reduced plastocyanin + plastoquinone. This reaction involves the concomitant transfer of 2 H+ ions across a membrane.


Lymphadenopathy with Polyclonal Hypergammaglobulinemia

A finding indicating the presence of enlarged lymph nodes and associated polyclonal hypergammaglobulinemia.


Localized enlarged lymph nodes

Lymphadenopathy restricted to nearby lymph nodes that has not affected other distal nodes.


Dermatopathic lymphadenitis

Regional lymph node enlargement with a distinctive reactive process that is characterized by paracortical hyperplasia composed of interdigitating dendritic cells, Langerhans cells, macrophages containing melanin pigment, and small T-cells, due to chronic inflammatory skin disease.


Atypical Lymph Node

A lymph node that deviates from usual in terms of size, shape, and internal architecture.


Recurrent Childhood Osteosarcoma

The reemergence of childhood osteosarcoma after a period of remission.


congenital or early infantile CACH syndrome


leukoencephalopathy with vanishing white matter

A new leukoencephalopathy, the CACH syndrome (Childhood Ataxia with Central nervous system Hypomyelination) or VWM (Vanishing White Matter) was identified on clinical and MRI criteria. Classically, this disease is characterized by (1) an onset between 2 and 5 years of age, with a cerebello-spastic syndrome exacerbated by episodes of fever or head trauma leading to death after 5 to 10 years of disease evolution, (2) a diffuse involvement of the white matter on cerebral MRI with a CSF-like signal intensity (cavitation), (3) a recessive autosomal mode of inheritance, (4) neuropathologic findings consistent with a cavitating orthochromatic leukodystrophy with increased number of oligodendrocytes with sometimes "foamy'' aspect.


leukoencephalopathy with vanishing white matter 5


leukoencephalopathy with vanishing white matter 2


leukoencephalopathy, progressive, with ovarian failure


leukoencephalopathy with vanishing white matter 3


leukoencephalopathy with vanishing white matter 1

Any leukoencephalopathy with vanishing white matter in which the cause of the disease is a variation in the EIF2B1 gene.


leukoencephalopathy with vanishing white matter 4


regulation of cellular hyperosmotic salinity response

Any process that modulates the frequency, rate or extent of cellular hyperosmotic salinity response.


negative regulation of cellular hyperosmotic salinity response

Any process that stops, prevents or reduces the frequency, rate or extent of cellular hyperosmotic salinity response.


olfactory bulb interneuron fate commitment

The process in which the developmental fate of a neuroblast becomes restricted such that it will develop into an interneuron residing in the olfactory bulb.


transient congenital hypothyroidism

A common, self-limiting thyroid disorder seen in preterm infants that is characterized by abnormally low serum levels of thyroxine and free thyroxine with normal serum levels of thyroid stimulating hormone.


bone dysplasia, lethal Holmgren type

Bone dysplasia lethal Holmgren type (BDLH) is a lethal bone dysplasia characterized at birth by low birth weight, a rhizomelic dwarfism, bent femora and short chest producing asphyxia. It was described in three siblings from healthy, non-consanguineous parents of Finnish and in four siblings from non-consanguineous parents of French origin with no family history of dwarfism. The initial cases could have been diagnosed as Desbuquois syndrome, or a recessive Larsen syndrome. There has been no further description of BDLH in the literature since 1988.


migraine, familial hemiplegic, 1

An autosomal dominant subtype of familial hemiplegic migraine caused by mutation(s) in the CACNA1A gene, encoding voltage-dependent P/Q-type calcium channel subunit alpha-1A.


saturated fatty acid

Any fatty acid containing no carbon to carbon multiple bonds. Known to produce adverse biological effects when ingested to excess.


branched-chain saturated fatty acid

Any saturated fatty acid with a carbon side-chain or isopropyl termination.


Recurrent Dedifferentiated Chordoma

The reemergence of dedifferentiated chordoma after a period of remission.


Recurrent Chordoma

The reemergence of chordoma after a period of remission.


Locally Recurrent Chordoma

The reemergence of chordoma after a period of remission, at or adjacent to the site of the original tumor.


Stage IV Primary Peritoneal Cancer AJCC v8

Stage IV includes: Any T, Any N, M1: M1: Distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)


Refractory Primary Peritoneal Endometrioid Adenocarcinoma

Primary peritoneal endometrioid adenocarcinoma that is resistant to treatment.


Refractory Primary Peritoneal Clear Cell Adenocarcinoma

Primary peritoneal clear cell adenocarcinoma that is resistant to treatment.


Recurrent Primary Peritoneal Clear Cell Adenocarcinoma

The reemergence of primary peritoneal clear cell adenocarcinoma after a period of remission.


Stage IIIB Primary Peritoneal Cancer AJCC v8

Stage IIIB includes: T3b, N0/N1, M0. T3b: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Advanced Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that has spread extensively from its original site of growth to other anatomic sites or is no longer responding to treatment.


Clear cell adenocarcinoma of peritoneum

An extremely rare adenocarcinoma arising from the peritoneum. It is composed of malignant glandular epithelium containing clear cells.


Refractory Primary Peritoneal Transitional Cell Carcinoma

Primary peritoneal transitional cell carcinoma that is resistant to treatment.


Refractory Primary Peritoneal Adenocarcinoma

Primary peritoneal adenocarcinoma that is resistant to treatment.


Metastatic Primary Peritoneal Carcinoma

A carcinoma that arises from the peritoneum and has metastasized to another anatomic site.


Stage III Primary Peritoneal Cancer AJCC v7

Stage III includes: T3, N0, M0.  T3: Microscopically confirmed peritoneal tumor outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)


Metastatic Primary Peritoneal High Grade Serous Adenocarcinoma

Primary peritoneal high-grade serous adenocarcinoma that has spread from its original site of growth to another anatomic site.


Stage IIIC Primary Peritoneal Cancer AJCC v7

Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal tumor beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)


Recurrent Primary Peritoneal Adenocarcinoma

The reemergence of primary peritoneal adenocarcinoma after a period of remission.


Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma

Primary peritoneal high-grade serous adenocarcinoma that is not amenable to surgical resection.


Refractory Primary Peritoneal Serous Adenocarcinoma

Primary peritoneal serous adenocarcinoma that is resistant to treatment.


Stage II Primary Peritoneal Cancer AJCC v8

Stage II includes: T2, N0, M0. T2: Primary peritoneal cancer. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Metastatic Primary Peritoneal Serous Adenocarcinoma

Primary peritoneal serous adenocarcinoma that has spread from its original site of growth to another anatomic site.


Stage IIA Primary Peritoneal Cancer AJCC v8

Stage IIA includes: T2a, N0, M0. T2a: Primary peritoneal cancer with extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Locally Advanced Unresectable Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma

The reemergence of primary peritoneal low grade serous adenocarcinoma after a period of remission.


Primary Peritoneal Transitional Cell Carcinoma

An extremely rare transitional cell carcinoma that arises from the peritoneum.


Platinum-Resistant Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that progresses between one and six months of completing the last platinum therapy.


Unresectable Primary Peritoneal Endometrioid Adenocarcinoma

Primary peritoneal endometrioid adenocarcinoma that is not amenable to surgical resection.


Primary Peritoneal Undifferentiated Carcinoma

An extremely rare carcinoma arising from the peritoneum. It is characterized by the presence of a diffuse malignant infiltrate that is composed of epithelial cells without evidence of glandular or squamous differentiation.


Unresectable Primary Peritoneal Serous Adenocarcinoma

Primary peritoneal serous adenocarcinoma that is not amenable to surgical resection.


Recurrent Primary Peritoneal Transitional Cell Carcinoma

The reemergence of primary peritoneal transitional cell carcinoma after a period of remission.


Stage IIIB Primary Peritoneal Cancer AJCC v7

Stage IIIB includes: T3b, N0, M0.  T3b: Macroscopic peritoneal tumor beyond pelvis 2 cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)


Refractory Primary Peritoneal High Grade Serous Adenocarcinoma

Primary peritoneal high grade serous adenocarcinoma that is resistant to treatment.


Recurrent Primary Peritoneal Undifferentiated Carcinoma

The reemergence of primary peritoneal undifferentiated carcinoma after a period of remission.


Refractory Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that is resistant to treatment.


Recurrent Platinum-Sensitive Primary Peritoneal Carcinoma

The reemergence of platinum-sensitive primary peritoneal carcinoma after a period of remission.


Primary Peritoneal Cancer by AJCC v8 Stage

A term that refers to the staging of primary peritoneal cancer according to the American Joint Committee on Cancer, 8th edition.


Primary Peritoneal Low Grade Serous Adenocarcinoma

A serous adenocarcinoma that arises from the lining of the peritoneum. It is characterized by low grade histopathologic features.


Stage III Primary Peritoneal Cancer AJCC v8

Stage III includes: IIIA: T3a, N0/N1, M0; IIIB: T3b, N0/N1, M0; IIIC: T3c, N0/N1, M0. T3a: Primary peritoneal cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. T3b: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. T3c: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Primary Peritoneal Cancer by AJCC v7 Stage

A term that refers to the staging of primary peritoneal cancer according to the American Joint Committee on Cancer, 7th edition.


Unresectable Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that is not amenable to surgical resection.


Primary Peritoneal Endometrioid Adenocarcinoma

An exceedingly rare endometrioid adenocarcinoma arising from the peritoneum.


Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma

The reemergence of primary peritoneal high-grade serous adenocarcinoma after a period of remission.


Metastatic Primary Peritoneal Adenocarcinoma

Primary peritoneal adenocarcinoma that has spread from its original site of growth to another anatomic site.


Primary Peritoneal Adenocarcinoma

A rare adenocarcinoma that arises from the lining of the peritoneum.


Stage IV Primary Peritoneal Cancer AJCC v7

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 7th Ed.)


Platinum-Refractory Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that progresses during platinum therapy or within one month of completing the last platinum therapy.


Unresectable Primary Peritoneal Adenocarcinoma

Primary peritoneal adenocarcinoma that is not amenable to surgical resection.


Stage IVA Primary Peritoneal Cancer AJCC v8

Stage IVA includes: Any T, Any N, M1a. M1a: Primary peritoneal cancer with pleural effusion with positive cytology. (from AJCC 8th Ed.)


Recurrent Primary Peritoneal Endometrioid Adenocarcinoma

The reemergence of primary peritoneal endometrioid adenocarcinoma after a period of remission.


Recurrent Primary Peritoneal Carcinoma

The reemergence of primary peritoneal carcinoma after a period of remission.


Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

The reemergence of platinum-resistant primary peritoneal carcinoma after a period of remission.


Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma

Primary peritoneal low grade serous adenocarcinoma that is resistant to treatment.


Stage IIIA Primary Peritoneal Cancer AJCC v7

Stage IIIA includes: T3a, N0, M0.  T3a: Microscopic peritoneal tumor beyond pelvis (no macroscopic tumor). N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)


Refractory Primary Peritoneal Undifferentiated Carcinoma

Primary peritoneal undifferentiated carcinoma that is resistant to treatment.


Locally Advanced Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IIIC Primary Peritoneal Cancer AJCC v8

Stage IIIC includes: T3c, N0/N1, M0. T3c: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Stage IIIA Primary Peritoneal Cancer AJCC v8

Stage IIIA includes: T3a, N0/N1, M0. T3a: Primary peritoneal cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Recurrent Primary Peritoneal Serous Adenocarcinoma

The reemergence of primary peritoneal serous adenocarcinoma after a period of remission.


Stage IIB Primary Peritoneal Cancer AJCC v8

Stage IIB includes: T2b, N0, M0. T2b: Primary peritoneal cancer with tumor extension to and/or implants on other pelvic tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Stage IVB Primary Peritoneal Cancer AJCC v8

Stage IVB includes: Any T, Any N, M1b. M1b: Primary peritoneal cancer with liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine. (from AJCC 8th Ed.)


Primary Peritoneal High Grade Serous Adenocarcinoma

A serous adenocarcinoma that arises from the lining of the peritoneum. It is characterized by high grade histopathologic features.


Platinum-Sensitive Primary Peritoneal Carcinoma

Primary peritoneal carcinoma that has a documented response to platinum-based chemotherapy.


glutamate catabolic process via 2-hydroxyglutarate

The anaerobic chemical reactions and pathways resulting in the breakdown of glutamate, via the intermediate 2-hydroxyglutarate, yielding energy in the form of ATP.


anaerobic glutamate catabolic process

The anaerobic chemical reactions and pathways resulting in the breakdown of glutamate, yielding energy in the form of ATP.


glutamate catabolic process via mesaconate and citramalate

The anaerobic chemical reactions and pathways resulting in the breakdown of glutamate via the intermediates mesaconate and S-citramalate, yielding energy in the form of ATP.


great vessel cancer

A malignant neoplasm arising from the great vessels.


Malignant Inferior Vena Cava Neoplasm

A malignant neoplasm involving the inferior vena cava.


pulmonary artery choriocarcinoma

A rare choriocarcinoma that arises from a pulmonary artery.


Malignant Superior Vena Cava Neoplasm

A malignant neoplasm involving the superior vena cava.


superior vena cava leiomyosarcoma

An aggressive malignant smooth muscle neoplasm, arising from the superior vena cava. It is characterized by a proliferation of neoplastic spindle cells.


Benign neoplasm of great vessels

A neoplasm that arises from the great vessels and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


aortic malignant tumor

A cancer that involves the aorta.


negative regulation of sperm capacitation

Any process that stops, prevents or reduces the frequency, rate or extent of sperm capacitation.


positive regulation of neuron remodeling

Any process that activates or increases the frequency, rate or extent of neuron remodeling.


regulation of neuron remodeling

Any process that modulates the frequency, rate or extent of neuron remodeling.


negative regulation of root hair elongation

Any process that stops, prevents or reduces the frequency, rate or extent of root hair elongation.


positive regulation of sperm capacitation

Any process that activates or increases the frequency, rate or extent of sperm capacitation.


negative regulation of erythrocyte enucleation

Any process that decreases the frequency, rate or extent of erythrocyte enucleation.


positive regulation of erythrocyte enucleation

Any process that increases the frequency, rate or extent of erythrocyte enucleation.


regulation of erythrocyte enucleation

Any process that modulates the frequency, rate or extent of erythrocyte enucleation.


positive regulation of bicoid mRNA localization

Any process that activates or increases the frequency, rate or extent of the process in which bicoid mRNA is transported to, or maintained in, a specific location.


negative regulation of meiotic cell cycle process involved in oocyte maturation

Any process that stops, prevents or reduces the frequency, rate or extent of meiotic cell cycle process involved in oocyte maturation.


regulation of sperm capacitation

Any process that modulates the frequency, rate or extent of sperm capacitation.


negative regulation of neuron remodeling

Any process that stops, prevents or reduces the frequency, rate or extent of neuron remodeling.


autosomal recessive complex spastic paraplegia due to kennedy pathway dysfunction


Metastatic Malignant Glomus Tumor

A malignant glomus tumor that has spread from its original site of growth to another anatomic site.


Locally Advanced Malignant Glomus Tumor

A malignant glomus tumor that has spread from its original site of growth to nearby tissues or lymph nodes.


Unresectable Malignant Glomus Tumor

A malignant glomus tumor that is not amenable to surgical resection.


Refractory Malignant Glomus Tumor

A malignant glomus tumor that is resistant to treatment.


Decreased Pigmentation

Decrease in the amount of pigment.


corticospinal neuron axon guidance through spinal cord

The process in which the migration of an axon growth cone of a pyramidal cell that is part of the corticospinal tract is directed after decussation through the spinal cord in response to a combination of attractive and repulsive cues.


sweat gland of eyelid

biolink:GrossAnatomicalStructure biolink:AnatomicalEntity biolink:OrganismalEntity biolink:BiologicalEntity biolink:NamedThing biolink:PhysicalEssence biolink:SubjectOfInvestigation biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

Glands of Moll, also known as ciliary glands, are modified apocrine sweat glands that are found on the margin of the eyelid. They are next to the base of the eyelashes, and anterior to the Meibomian glands within the distal eyelid margin. These glands are relatively large and tubular-shaped. The glands of Moll are named after Dutch oculist Jacob Anton Moll (1832-1914). Glands of Moll empty into the adjacent lashes. Glands of Moll and Zeis secrete lipid that adds to the superficial layer of the tear film, retarding evaporation. The glands of Moll are prone to infection and blockage of its duct with sebum and cell debris. Blockage of the gland's duct causes swelling which can manifest itself as a stye.


eyelid gland

Any gland that is part of an eyelid. This includes sebaceous glands (Zeis gland, tarsal gland) and sweat glands (Moll's gland).


gland of Zeis

Glands of Zeis are unilobar sebaceous glands located on the margin of the eyelid. The glands of Zeis service the eyelash. These glands produce an oily substance that is issued through the excretory ducts of the sebaceous lobule into the middle portion of the hair follicle.


sebaceous gland of eyelid

Any of the sebaceous glands that are in the eyelid. Examples: gland of Zeis (services eyelashes), gland of Meibom (tarsal gland - unconnected to eyelids).


Ciaccio's gland

Ciaccio's glands are small tubular accessory lacrimal glands (glandulae lacrimales accessoriae) found in the lacrimal caruncle of the eyelid. They are located in the upper border of the tarsus, approximately in the middle between the extremities of the tarsal glands. Sometimes they are situated slightly above the tarsus. There are usually 2 to 5 of these glands in the upper eyelid, and their function is to produce tears which are secreted onto the surface of the conjunctiva. They are named after Italian anatomist Giuseppe Vincenzo Ciaccio (1824b1901), who described these glands in 1874. They are sometimes called Wolfring's glands after Polish ophthalmologist Emilj von Wolfring (1832-1906), who described them during the same time period as did Ciaccio. Another type of accessory lacrimal gland are Krause's glands, which are smaller, more numerous than Ciaccio's glands and are found along the superior and inferior fornices of the conjunctival sac.


Stage III Fallopian Tube Cancer AJCC v6

Stage III includes: (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T3b, N0, M0); IIIC (T3c, N0, M0).  T3: Tumor involves one or both fallopian tubes, with peritoneal implants outside the pelvis.  T3a: Microscopic peritoneal metastasis outside the pelvis.  T3b: Macroscopic peritoneal metastasis outside the pelvis 2cm or less in greatest dimension.  T3c: Peritoneal metastasis more than 2cm in diameter. (AJCC 6th ed.)


proline salvage

Any process which produces the amino acid proline from derivatives of it, without de novo synthesis.


intellectual disability-feeding difficulties-developmental delay-microcephaly syndrome


Stage IA2 Lung Cancer AJCC v8

Stage IA2 includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


long nephron

Long nephrons are associated with juxtamedullary glomeruli and extend to the inner medulla.


lipoprotein biosynthetic process via signal peptide cleavage

The chemical reactions and pathways by which signal peptide cleavage leads to formation of a water-soluble protein-lipid complex.


structural constituent of egg coat

The action of a molecule that contributes to the structural integrity of an egg coat. An egg coat is a specialized extracellular matrix that surrounds the ovum of animals. The egg coat provides structural support and can play an essential role in oogenesis, fertilization and early development.


ocular dysgenesis caused by defects in PAX6 regulation

Any eye disorder in which the cause of the disease is a variant in the PAX6 gene itself or a variant within another locus that results in defective regulation of the PAX6 gene.


UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase activity

Catalysis of the removal of an acetyl group from the 2-N position of glucosamine in the lipid A precursor UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine.


Metastatic malignant neoplasm to prostate

The spread of a malignant neoplasm to the prostate gland from an adjacent or distant anatomic site.


Metastatic Malignant Neoplasm in the Male Reproductive System

The spread of a malignant neoplasm to the male reproductive system from an adjacent or distant anatomic site.


Secondary Prostate Urothelial Carcinoma

A transitional cell carcinoma that has spread to the prostate gland directly from the bladder.


Metastatic malignant neoplasm to seminal vesicle

The spread of a malignant neoplasm to the seminal vesicle from an adjacent or distant anatomic site.


Metastatic malignant neoplasm to testis

A malignant neoplasm that has spread to the testis from another anatomic site.


Metastatic malignant neoplasm to epididymis

A malignant neoplasm that has metastasized to the epididymis from another anatomic site.


Metastatic malignant neoplasm to penis

The spread of a malignant neoplasm to the penis from an adjacent or distant anatomic site.


pupal chitin-based cuticle development

Synthesis and deposition of a chitin-based pupal cuticle. At the end of the prepupal period the insect is covered by the pupal cuticle which continues to be elaborated into the pupal period. An example of this is found in Drosophila melanogaster.


atrazine catabolic process to urea

The chemical reactions and pathways resulting in the breakdown of atrazine, a triazine ring-containing herbicide, into urea.


formamide catabolic process

The chemical reactions and pathways resulting in the breakdown of formamide, the simplest amide, HCONH2, derived from formic acid.


urea catabolic process

The chemical reactions and pathways resulting in the breakdown of urea, the water soluble compound O=C-(NH2)2.


allantoin assimilation pathway

The pathways by which allantoin is processed and converted to ureidoglycolate, and then into metabolically useful substrates. E. coli are able to utilize allantoin as a sole nitrogen source under anaerobic conditions by converting it to ureidoglycolate; this may be further metabolized to produce glyoxylate and thence 3-phosphoglycerate, or alternatively oxidized to oxolureate, which can converted into oxamate and carbamoylphosphate. This may then be further metabolized to CO2, NH4+ and ATP.


allantoin catabolic process

The chemical reactions and pathways resulting in the breakdown of allantoin, (2,5-dioxo-4-imidazolidinyl)urea.


biotin catabolic process

The chemical reactions and pathways resulting in the breakdown of biotin, cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid.


adenine deaminase activity

Catalysis of the reaction: adenine + H2O = hypoxanthine + NH3.


A cholangiocarcinoma that has developed following infection with Opisthorchis viverrini.


Stage 0 Hilar Cholangiocarcinoma AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ/high grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Locally Advanced Distal Bile Duct Carcinoma

Distal bile duct carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7

Stage IVB includes: Any T, Any N, M1.  M1: Distant metastasis. (from AJCC 7th Ed.)


Stage IA Intrahepatic Cholangiocarcinoma AJCC v8

Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal or less than 5 cm without vascular invasion.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Cholangiocarcinoma resectable

Cholangiocarcinoma that is amenable to surgical resection.


Metastatic Bile Duct Carcinoma

A carcinoma that arises from the intrahepatic or extrahepatic bile ducts and has metastasized to other anatomic sites.


Advanced Extrahepatic Bile Duct Carcinoma

Extrahepatic bile duct carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage IVB Hilar Cholangiocarcinoma AJCC v8

Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Stage IB Distal Bile Duct Cancer AJCC v7

Stage IB includes: T2, N0, M0. T2: Tumor invades beyond the wall of the bile duct.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Localized Extrahepatic Bile Duct Carcinoma

A carcinoma that arises from the extrahepatic bile ducts and it has not spread to other anatomic sites.


Stage IIIB Hilar Cholangiocarcinoma AJCC v7

Stage IIIB includes: T1-3, N1, M0. T1: Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue.  T2a: Tumor invades beyond the wall of the bile duct to surrounding adipose tissue.  T2b: Tumor invades adjacent hepatic parenchyma.  T3: Tumor invades unilateral branches of the portal vein or hepatic artery.  N1: Regional lymph node metastasis (including nodes along the cystic duct, common bile duct, hepatic artery, and portal vein).  M0: No distant metastasis. (from AJCC 7th Ed.)


Hilar Cholangiocarcinoma by AJCC v7 Stage

A term that refers to the staging of hilar cholangiocarcinoma according to the American Joint Committee on Cancer, 7th edition.


Cholangiocarcinoma non-resectable

Cholangiocarcinoma that is not amenable to surgical resection.


Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7

Stage IVA includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor with periductal invasion. N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Distal Bile Duct Adenocarcinoma

An adenocarcinoma that arises from the common bile duct distal to the insertion of the cystic duct.


Clear Cell Intrahepatic Cholangiocarcinoma

A morphologic variant of intrahepatic cholangiocarcinoma composed of malignant glandular epithelium, an abundant fibrous stroma, and the presence of clear cells. Clinical symptoms include abdominal pain, weight loss and malaise.


Stage I Distal Bile Duct Cancer AJCC v8

Stage I includes: T1, N0, M0. T1: Tumor invading the bile duct wall with a depth less than 5 mm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Metastatic Hilar Cholangiocarcinoma

Hilar cholangiocarcinoma that has spread from its original site of growth to another anatomic site.


Stage IIIC Hilar Cholangiocarcinoma AJCC v8

Stage IIIC includes: Any T, N1, M0. N1: One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Unresectable Distal Bile Duct Adenocarcinoma

Distal bile duct adenocarcinoma that is not amenable to surgical resection.


Recurrent Distal Bile Duct Adenocarcinoma

The reemergence of distal bile duct adenocarcinoma after a period of remission.


Extrahepatic Bile Duct Neuroendocrine Carcinoma

An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the extrahepatic bile ducts. The mitotic count is more than 20 per 10 HPF. According to the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm, it is classified either as small or large cell neuroendocrine carcinoma.


Stage I Hilar Cholangiocarcinoma AJCC v7

Stage I includes: T1, N0, M0. T1: Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Locally Advanced Unresectable Cholangiocarcinoma

Cholangiocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Stage IV Hilar Cholangiocarcinoma AJCC v8

Stage IV includes: IVA: (Any T, N2, M0); IVB: (Any T, Any N, M1). N2: Four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Bile duct cancer resectable

Extrahepatic bile duct carcinoma that is amenable to surgical removal.


Locally Advanced Bile Duct Carcinoma

A bile duct carcinoma that has spread to nearby tissues or lymph nodes.


Metastatic cholangiocarcinoma

A cholangiocarcinoma that has metastasized to other anatomic sites.


Advanced Bile Duct Carcinoma

A carcinoma that arises from the intrahepatic or extrahepatic bile ducts and has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage IVA Hilar Cholangiocarcinoma AJCC v7

Stage IVA includes: T4, N0-1, M0. T4: Tumor invades the main portal vein or its branches bilaterally; or the common hepatic artery; or the second-order biliary radicals bilaterally; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement.  N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis (including nodes along the cystic duct, common bile duct, hepatic artery, and portal vein).  M0: No distant metastasis.  (from AJCC 7th Ed.)


Locally Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Metastatic Distal Bile Duct Adenocarcinoma

Distal bile duct adenocarcinoma that has spread from its original site of growth to another anatomic site.


intestinal type adenocarcinoma of extrahepatic bile duct

An adenocarcinoma that arises from the extrahepatic bile ducts.  It is characterized by the presence of neoplastic tubular glands lined by columnar cells or neoplastic glands lined by goblet cells.


Bile duct cancer recurrent

The reemergence of bile duct carcinoma after a period of remission.


Stage III Intrahepatic Cholangiocarcinoma AJCC v8

Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); (Any T, N1, M0). T3: Tumor perforating the visceral peritoneum. T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Distal Bile Duct Cancer AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Intrahepatic cholangiocarcinoma that has metastasized to a limited number of sites.


Stage III Intrahepatic Cholangiocarcinoma AJCC v7

Stage III includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum or involving the local extra hepatic structures by direct invasion. N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IIIA Distal Bile Duct Cancer AJCC v8

Stage IIIA includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Refractory Bile Duct Carcinoma

Bile duct carcinoma that is resistant to treatment.


Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8

Stage IIIB includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


The reemergence of intrahepatic cholangiocarcinoma after a period of remission.


Recurrent Extrahepatic Bile Duct Carcinoma

The reemergence of an extrahepatic bile duct carcinoma after a period of remission.


Refractory Extrahepatic Bile Duct Carcinoma

Extrahepatic bile duct carcinoma that is resistant to treatment.


anaplastic carcinoma of extrahepatic bile duct

A carcinoma without evidence of differentiation arising from the extrahepatic bile ducts.


Hilar Cholangiocarcinoma by AJCC v8 Stage

A term that refers to the staging of hilar cholangiocarcinoma according to the American Joint Committee on Cancer, 8th edition. Hilar well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)


Stage 0 Intrahepatic Cholangiocarcinoma AJCC v7

Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ (intraductal tumor).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage II Distal Bile Duct Cancer AJCC v8

Stage II includes: IIA: (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IVA Hilar Cholangiocarcinoma AJCC v8

Stage IVA includes: Any T, N2, M0. N2: Four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage I Hilar Cholangiocarcinoma AJCC v8

Stage I includes: T1, N0, M0. T1: Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Hilar Cholangiocarcinoma AJCC v8

Stage II includes: T2a-b, N0, M0. T2a: Tumor invading beyond the wall of the bile duct to surrounding adipose tissue. T2b: Tumor invading adjacent hepatic parenchyma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Intrahepatic Cholangiocarcinoma AJCC v8

Stage II includes: T2, N0, M0. T2: Solitary tumor with intrahepatic vascular invasion, or multiple tumors, with or without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Bile Duct Papillary Neoplasm with an Associated Invasive Carcinoma

An intraductal papillary neoplasm that arises from the epithelium of the intrahepatic or extrahepatic bile ducts and it is associated with an invasive carcinomatous component.


Intrahepatic Cholangiocarcinoma by AJCC v8 Stage

A term that refers to the staging of intrahepatic cholangiocarcinoma according to the American Joint Committee on Cancer, 8th edition.


Stage IV Intrahepatic Cholangiocarcinoma AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Stage IIB Distal Bile Duct Cancer AJCC v7

Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Tumor confined to the bile duct histologically.  T2: Tumor invades beyond the wall of the bile duct. T3: Tumor invades the gallbladder, pancreas, duodenum, or other adjacent organs without involvement of the celiac axis or the superior mesenteric artery.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IIIA Hilar Cholangiocarcinoma AJCC v8

Stage IIIA includes: T3, N0, M0. T3: Tumor invading unilateral branches of the portal vein or hepatic artery. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Distal Bile Duct Cancer by AJCC v8 Stage

A term that refers to the staging of distal bile duct cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to bile duct adenocarcinomas, biliary intraepithelial neoplasia, high-grade neuroendocrine carcinomas, and papillary carcinomas that arise from the distal bile duct. Tumors arising in the ampulla of Vater, sarcomas, and well-differentiated neuroendocrine tumors (carcinoids) are not staged using this staging system. (from AJCC 8th Ed.)


Metastatic Extrahepatic Bile Duct Carcinoma

Extrahepatic bile duct carcinoma that has spread from its original site of growth to another anatomic site.


Extrahepatic Bile Duct Adenocarcinoma, Biliary Type

A well or moderately differentiated adenocarcinoma that arises from the extrahepatic bile ducts.  It is characterized by the presence of malignant tubular glands.


Stage IB Intrahepatic Cholangiocarcinoma AJCC v8

Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


carcinosarcoma of extrahepatic bile duct

A carcinoma that arises from the extrahepatic bile ducts and it is characterized by the presence of a sarcomatous component.


Stage IV Distal Bile Duct Cancer AJCC v7

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis.  (from AJCC 7th Ed.)


Stage IIB Distal Bile Duct Cancer AJCC v8

Stage IIB includes: (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage 0 Hilar Cholangiocarcinoma AJCC v7

Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IA Distal Bile Duct Cancer AJCC v7

Stage IA includes: T1, N0, M0. T1: Tumor confined to the bile duct histologically.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Locally Advanced Extrahepatic Bile Duct Carcinoma

Extrahepatic bile duct carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Unresectable Bile Duct Carcinoma

Bile duct carcinoma that is not amenable to surgical resection.


Stage IIIB Distal Bile Duct Cancer AJCC v8

Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IVB Hilar Cholangiocarcinoma AJCC v7

Stage IVB includes: (Any T, N2, M0); (Any T, Any N, M1).  N2: MetastasIs to periaortic, pericaval, superior mesenteric artery, and/or celiac artery lymph nodes.  M0: No distant metastasis.  M1: Distant metastasis. (from AJCC 7th Ed.)


Intrahepatic cholangiocarcinoma that has spread from its original site of growth to another anatomic site.


Extrahepatic Bile Duct Mixed Adenoneuroendocrine Carcinoma

A carcinoma that arises from the extrahepatic bile ducts and is characterized by the presence of a malignant glandular epithelial component and a malignant neuroendocrine component.  At least 30 percent of either component should be present for the diagnosis to be made.


Unresectable Hilar Cholangiocarcinoma

Hilar cholangiocarcinoma that is not amenable to surgical resection.


Stage III Hilar Cholangiocarcinoma AJCC v8

Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); IIIC: (Any T, N1, M0). T3: Tumor invading unilateral branches of the portal vein or hepatic artery. T4: Tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. N0: No regional lymph node metastasis. N1: One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Intrahepatic Cholangiocarcinoma by AJCC v7 Stage

A term that refers to the staging of intrahepatic cholangiocarcinoma according to the American Joint Committee on Cancer, 7th edition.


Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8

Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIA Distal Bile Duct Cancer AJCC v8

Stage IIA includes: (T1, N1, M0); (T2, N0, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Intrahepatic Cholangiocarcinoma AJCC v7

Stage II includes: T2, N0, M0.  T2: Solitary tumor with vascular invasion or multiple tumors, with or without vascular invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Refractory Distal Bile Duct Adenocarcinoma

Distal bile duct adenocarcinoma that is resistant to treatment.


Metastatic Distal Bile Duct Carcinoma

A distal bile duct carcinoma that has spread from its original site of growth to other anatomic sites.


Extrahepatic Bile Duct Intraductal Papillary Neoplasm with an Associated Invasive Carcinoma

A papillary neoplasm that arises from the epithelium of the extrahepatic bile ducts and it is associated with an invasive carcinomatous component.  The carcinomatous component is an adenocarcinoma.


Intrahepatic cholangiocarcinoma that is amenable to surgical resection.


Stage IIA Distal Bile Duct Cancer AJCC v7

Stage IIA includes: T3, N0, M0.  T3: Tumor invades the gallbladder, pancreas, duodenum, or other adjacent organs without involvement of the celiac axis or the superior mesenteric artery.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Cholangiocarcinoma recurrent

The reemergence of cholangiocarcinoma after a period of remission.


Small Duct Intrahepatic Cholangiocarcinoma

An intrahepatic cholangiocarcinoma that arises from the small interlobular bile ducts.


Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intraductal tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Distal Bile Duct Cancer by AJCC v7 Stage

A term that refers to the staging of distal bile duct cancer according to the American Joint Committee on Cancer, 7th edition.


Intrahepatic cholangiocarcinoma that is resistant to treatment.


Extrahepatic Bile Duct Adenocarcinoma, Gastric Foveolar Type

An unusual, well differentiated adenocarcinoma that arises from the extrahepatic bile ducts.  It is characterized by the presence of tall malignant columnar cells with mucin-containing cytoplasm and basally located nuclei.


Intrahepatic cholangiocarcinoma that is not amenable to surgical removal.


Stage II Hilar Cholangiocarcinoma AJCC v7

Stage II includes: T2a-b, N0, M0.  T2a: Tumor invades beyond the wall of the bile duct to surrounding adipose tissue.  T2b: Tumor invades adjacent hepatic parenchyma.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage III Distal Bile Duct Cancer AJCC v7

Stage III includes: T4, Any N, M0. T4: Tumor involves the celiac axis or the superior mesenteric artery.  M0: No distant metastasis. (from AJCC 7th Ed.)


Locally Advanced Cholangiocarcinoma

Cholangiocarcinoma that has spread to nearby tissues or lymph nodes.


Stage I Intrahepatic Cholangiocarcinoma AJCC v8

Stage I includes: IA (T1a, N0, M0); IB (T1b, N0, M0). T1a: Solitary tumor equal or less than 5 cm without vascular invasion.  T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Unresectable Extrahepatic Bile Duct Carcinoma

Extrahepatic bile duct carcinoma that is not amenable to surgical removal.


Stage IIIB Hilar Cholangiocarcinoma AJCC v8

Stage IIIB includes: T4, N0, M0. T4: Tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Resectable Extrahepatic Bile Duct Adenocarcinoma

Extrahepatic bile duct adenocarcinoma that is amenable to surgical resection.


Stage IIIA Hilar Cholangiocarcinoma AJCC v7

Stage IIIA includes: T3, N0, M0. T3: Tumor invades unilateral branches of the portal vein or hepatic artery.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Intrahepatic Bile Duct Intraductal Papillary Neoplasm with an Associated Invasive Carcinoma

A papillary neoplasm that arises from the epithelium of the intrahepatic bile ducts and it is associated with an invasive carcinomatous component.  The carcinomatous component is an intrahepatic cholangiocarcinoma.


Stage I Intrahepatic Cholangiocarcinoma AJCC v7

Stage I includes: T1, N0, M0. T1: Solitary tumor without vascular invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage III Distal Bile Duct Cancer AJCC v8

Stage III includes: IIIA: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Bile duct adenocarcinoma resectable

Bile duct adenocarcinoma that is amenable to surgical resection.


Extrahepatic Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma

A mucinous cystic neoplasm that arises from the extrahepatic bile ducts and it is associated with an invasive carcinomatous component.


Stage 0 Distal Bile Duct Cancer AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ/high-grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage 0 Distal Bile Duct Cancer AJCC v7

Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Refractory Cholangiocarcinoma

Cholangiocarcinoma that is resistant to treatment.


large cell neuroendocrine carcinoma of extrahepatic bile duct

An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the extrahepatic bile ducts.  It is characterized by the presence of malignant large cells.


positive regulation of metanephric cap mesenchymal cell proliferation

Any process that increases the frequency, rate, or extent of metanephric cap mesenchymal cell proliferation. Metanephric cap mesenchymal cell proliferation is the multiplication or reproduction of metanephric cap mesenchymal cells, resulting in the expansion of the cell population. A metanephric cap mesenchymal cell is a mesenchymal cell that has condensed with other mesenchymal cells surrounding the ureteric bud tip.


lumbar nerve

biolink:AnatomicalEntity biolink:OrganismalEntity biolink:BiologicalEntity biolink:NamedThing biolink:PhysicalEssence biolink:SubjectOfInvestigation biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

The lumbar nerves are the five spinal nerves emerging from the lumbar vertebrae. They are divided into posterior and anterior divisions.


statocyst

A balance sensory receptor present in some aquatic invertebrates[WP].


choroid spindle cell melanoma

A spindle cell melanoma that involves the optic choroid.


choroid epithelioid cell melanoma

A epithelioid cell melanoma that involves the optic choroid.


choroid necrotic melanoma

A choroid melanoma characterized by the presence of tumor cell necrosis.


choroid mixed cell melanoma

A mixed cell uveal melanoma that involves the optic choroid.


intermediate cell type choroid melanoma

Choroid melanoma characterized by the presence of intermediate cells which are similar to but smaller than epithelioid cells.


fumaric aciduria

Fumaric aciduria (FA), an autosomal recessive metabolic disorder, is most often characterized by early onset but non-specific clinical signs: hypotonia, severe psychomotor impairment, convulsions, respiratory distress, feeding difficulties and frequent cerebral malformations, along with a distinctive facies. Some patients present with only moderate intellectual impairment.


vein of appendix

A vein that is part of a vermiform appendix.


Ankle Injuries

Trauma to the ankle joint.


hyomandibula-metapterygoid joint

Joint that articulates the hyomandibula bone and metapterygoid bone.


vertebral artery insufficiency

A syndrome which occurs as a result of the occlusion of one of the vertebral arteries. It may be caused by atherosclerosis, embolism or hemorrhage. Collateral circulation through the circle of Willis is usually comprised as well. Clinical signs may include vertigo, nystagmus, dysarthria, ataxia and sensorimotor deficits. Clinical course may lead to persistence of neurologic deficits. Prognosis is variable with a substantial risk for recurrent infarction.


2-oxoglutarate oxygenase/decarboxylase (ethylene-forming) activity

Catalysis of the reaction: 2-oxoglutarate(2-) + O2 + 2 H+ = ethene + 3 carbon dioxide + H2O.


negative regulation of penicillin catabolic process

Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways leading to the breakdown of any antibiotic that contains the condensed beta-lactamthiazolidine ring system.


negative regulation of lysine biosynthetic process via alpha-aminoadipate and saccharopine

Any process that stops, prevents or reduces the frequency, rate or extent of lysine biosynthetic process via alpha-aminoadipate and saccharopine.


negative regulation of fumonisin biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of fumonisin biosynthetic process.


regulation of initiation of acetate catabolic process by acetate

Any process that modulates the activation, by acetate, of the chemical reactions and pathways resulting in the breakdown of acetate.


negative regulation of tetrapyrrole biosynthetic process from glutamate

Any process that stops, prevents or reduces the frequency, rate or extent of tetrapyrrole biosynthetic process from glutamate.


negative regulation of tensidol A biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of tensidol A biosynthetic process.


regulation of polyketide biosynthetic process

Any process that modulates the frequency, rate or extent of polyketide biosynthetic process.


regulation of citrulline biosynthetic process

Any process that modulates the frequency, rate or extent of citrulline biosynthetic process.


regulation of arginine catabolic process

Any process that modulates the frequency, rate or extent of arginine catabolic process.


positive regulation of androst-4-ene-3,17-dione biosynthetic process

Any process that activates or increases the frequency, rate or extent of androst-4-ene-3,17-dione biosynthetic process.


positive regulation of L-glutamine biosynthetic process

Any process that starts, increases the frequency, rate or extent of L-glutamine biosynthesis.


regulation of proline biosynthetic process

Any process that modulates the frequency, rate or extent of proline biosynthetic process.


negative regulation of retinoic acid biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of retinoic acid biosynthetic process.


negative regulation of androst-4-ene-3,17-dione biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of androst-4-ene-3,17-dione biosynthetic process.


positive regulation of ecdysteroid biosynthetic process

Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ecdysteroids.


positive regulation of leucine biosynthetic process

Any process that activates or increases the frequency, rate or extent of leucine biosynthetic process.


regulation of L-dopa biosynthetic process

Any process that modulates the frequency, rate or extent of L-dopa biosynthetic process.


regulation of 'de novo' NAD biosynthetic process from tryptophan

Any process that modulates the frequency, rate or extent of 'de novo' NAD biosynthetic process from tryptophan.


negative regulation of citrulline biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of citrulline biosynthetic process.


negative regulation of xanthone-containing compound biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of xanthone-containing compound biosynthetic process.


negative regulation of gibberellin biosynthetic process

Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of gibberellins.


negative regulation of palmitic acid catabolic process

Any process that stops, prevents or reduces the frequency, rate or extent of a palmitic acid catabolic process.


negative regulation of lysine biosynthetic process via aminoadipic acid

Any process that stops, prevents or reduces the frequency, rate or extent of lysine biosynthetic process via aminoadipic acid.


positive regulation of palmitic acid catabolic process

Any process that activates or increases the frequency, rate or extent of a palmitic acid catabolic process.


regulation of L-glutamine biosynthetic process

Any process that modulates the rate, frequency or extent of L-glutamine biosynthesis.


regulation of asperthecin biosynthetic process

Any process that modulates the frequency, rate or extent of asperthecin biosynthetic process.


negative regulation of butyryl-CoA biosynthetic process from acetyl-CoA

Any process that stops, prevents or reduces the frequency, rate or extent of butyryl-CoA biosynthetic process from acetyl-CoA.


regulation of butyryl-CoA biosynthetic process from acetyl-CoA

Any process that modulates the frequency, rate or extent of butyryl-CoA biosynthetic process from acetyl-CoA.


regulation of F-9775A biosynthetic process

Any process that modulates the frequency, rate or extent of F-9775A biosynthetic process.


regulation of ferulate catabolic process

Any process that modulates the frequency, rate or extent of ferulate catabolic process.


regulation of lysine biosynthetic process via alpha-aminoadipate and saccharopine

Any process that modulates the frequency, rate or extent of lysine biosynthetic process via alpha-aminoadipate and saccharopine.


negative regulation of leucine biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of leucine biosynthetic process.


regulation of naphtho-gamma-pyrone biosynthetic process

Any process that modulates the frequency, rate or extent of naphtho-gamma-pyrone biosynthetic process.


regulation of helvolic acid biosynthetic process

Any process that modulates the frequency, rate or extent of helvolic acid biosynthetic process.


regulation of butyryl-CoA catabolic process to butyrate

Any process that modulates the frequency, rate or extent of butyryl-CoA catabolic process to butyrate.


regulation of gamma-aminobutyric acid catabolic process

Any process that modulates the frequency, rate or extent of gamma-aminobutyric acid catabolic process.


regulation of gerfelin biosynthetic process

Any process that modulates the frequency, rate or extent of gerfelin biosynthetic process.


regulation of arginine biosynthetic process via ornithine

Any process that modulates the frequency, rate or extent of arginine biosynthetic process via ornithine.


negative regulation of L-ascorbic acid biosynthetic process

Any process that stops, prevents, or reduces the frequency, rate or extent of L-ascorbic acid biosynthetic process.


regulation of palmitic acid catabolic process

Any process that modulates the frequency, rate or extent of a palmitic acid catabolic process.


negative regulation of L-glutamine biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of L-glutamine biosynthesis.


regulation of asperfuranone biosynthetic process

Any process that modulates the frequency, rate or extent of asperfuranone biosynthetic process.


regulation of progesterone biosynthetic process

Any process that modulates the frequency, rate or extent of progesterone biosynthetic process.


negative regulation of isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway

Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of isopentenyl diphosphate produced via the methylerythritol (MEP) pathway (mevalonate-independent).


negative regulation of abscisic acid biosynthetic process

Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of abscisic acid.


regulation of ecdysteroid metabolic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving ecdysteroids, a group of polyhydroxylated ketosteroids which initiate post-embryonic development, including the metamorphosis of immature forms and the development of the reproductive system and the maturation of oocytes in adult females.


negative regulation of ubiquinone biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of ubiquinone biosynthetic process.


negative regulation of monodictyphenone biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of monodictyphenone biosynthetic process.


positive regulation of bile acid biosynthetic process

Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of bile acids.


regulation of tryptophan metabolic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving tryptophan, the chiral amino acid 2-amino-3-(1H-indol-3-yl)propanoic acid.


regulation of ketone catabolic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a ketone, carried out by individual cells.


positive regulation of initiation of acetate catabolic process by acetate

Any process that activates or increases the frequency, rate or extent of the activation, by acetate, of the chemical reactions and pathways resulting in the breakdown of acetate.


positive regulation of kojic acid biosynthetic process

Any process that activates or increases the frequency, rate or extent of kojic acid biosynthetic process.


regulation of jasmonic acid biosynthetic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of jasmonic acid.


regulation of tensidol A biosynthetic process

Any process that modulates the frequency, rate or extent of tensidol A biosynthetic process.


negative regulation of homocysteine metabolic process

Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving homocysteine.


regulation of proline catabolic process to glutamate

Any process that modulates the frequency, rate or extent of proline catabolic process to glutamate.


positive regulation of penicillin catabolic process

Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways leading to the breakdown of any antibiotic that contains the condensed beta-lactamthiazolidine ring system.


positive regulation of fatty acid beta-oxidation using acyl-CoA dehydrogenase

Any process that activates or increases the frequency, rate or extent of fatty acid beta-oxidation using acyl-CoA dehydrogenase.


negative regulation of ferulate catabolic process

Any process that stops, prevents or reduces the frequency, rate or extent of ferulate catabolic process.


negative regulation of tetrapyrrole biosynthetic process from glycine and succinyl-CoA

Any process that stops, prevents or reduces the frequency, rate or extent of tetrapyrrole biosynthetic process from glycine and succinyl-CoA.


negative regulation of acetate catabolic process

Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of acetate.


positive regulation of methane biosynthetic process from formic acid

Any process that activates or increases the frequency, rate or extent of methane biosynthetic process from formic acid.


negative regulation of proline catabolic process to glutamate

Any process that stops, prevents or reduces the frequency, rate or extent of proline catabolic process to glutamate.


positive regulation of penicillin metabolic process

Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving any antibiotic that contains the condensed beta-lactamthiazolidine ring system.


positive regulation of ferulate catabolic process

Any process that activates or increases the frequency, rate or extent of ferulate catabolic process.


negative regulation of gamma-aminobutyric acid catabolic process

Any process that stops, prevents or reduces the frequency, rate or extent of gamma-aminobutyric acid catabolic process.


regulation of cysteine metabolic process

Any process that modulates the frequency, rate or extent of cysteine metabolic process.


positive regulation of cysteine metabolic process

Any process that activates or increases the frequency, rate or extent of cysteine metabolic process.


positive regulation of butyryl-CoA biosynthetic process from acetyl-CoA

Any process that activates or increases the frequency, rate or extent of butyryl-CoA biosynthetic process from acetyl-CoA.


negative regulation of naphtho-gamma-pyrone biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of naphtho-gamma-pyrone biosynthetic process.


regulation of endocrocin biosynthetic process

Any process that modulates the frequency, rate or extent of endocrocin biosynthetic process.


regulation of ubiquinone biosynthetic process

Any process that modulates the frequency, rate or extent of ubiquinone biosynthesis. Ubiquinone biosynthesis consists of the chemical reactions and pathways resulting in the formation of ubiquinone, a lipid-soluble electron-transporting coenzyme.


negative regulation of testosterone biosynthetic process

Any process that stops, prevents, or reduces the frequency, rate or extent of testosterone biosynthetic process.


negative regulation of selenocysteine metabolic process

Any process that stops, prevents or reduces the frequency, rate or extent of selenocysteine metabolic process.


negative regulation of tensidol B biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of tensidol B biosynthetic process.


regulation of isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of isopentenyl diphosphate produced via the methylerythritol (MEP) pathway (mevalonate-independent).


regulation of F-9775B biosynthetic process

Any process that modulates the frequency, rate or extent of F-9775B biosynthetic process.


negative regulation of initiation of acetate catabolic process by acetate

Any process that stops or prevents the activation, by acetate, of the chemical reactions and pathways resulting in the breakdown of acetate.


negative regulation of indoleacetic acid biosynthetic process via tryptophan

Any process that stops, prevents or reduces the frequency, rate or extent of indoleacetic acid biosynthetic process via tryptophan.


positive regulation of tryptophan metabolic process

Any process that increases the frequency, rate or extent of the chemical reactions and pathways involving tryptophan, the chiral amino acid 2-amino-3-(1H-indol-3-yl)propanoic acid.


regulation of lysine biosynthetic process via aminoadipic acid

Any process that modulates the frequency, rate or extent of lysine biosynthetic process via aminoadipic acid.


negative regulation of penicillin biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of penicillin biosynthetic process.


negative regulation of ammonia assimilation cycle

Any process that stops, prevents or reduces the frequency, rate or extent of ammonia assimilation cycle.


negative regulation of glutamate metabolic process

Any process that stops, prevents, or reduces the frequency, rate or extent of glutamate metabolic process.


positive regulation of abscisic acid biosynthetic process

Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of abscisic acid.


positive regulation of ubiquinone biosynthetic process

Any process that activates or increases the frequency, rate or extent of ubiquinone biosynthetic process.


negative regulation of methane biosynthetic process from 3-(methylthio)propionic acid

Any process that stops, prevents or reduces the frequency, rate or extent of methane biosynthetic process from 3-(methylthio)propionic acid.


regulation of glyoxylate cycle

Any process that modulates the frequency, rate or extent of glyoxylate cycle.


positive regulation of progesterone biosynthetic process

Any process that activates or increases the frequency, rate or extent of progesterone biosynthetic process.


regulation of penicillin biosynthetic process

Any process that modulates the frequency, rate or extent of penicillin biosynthetic process.


regulation of methane biosynthetic process from 3-(methylthio)propionic acid

Any process that modulates the frequency, rate or extent of methane biosynthetic process from 3-(methylthio)propionic acid.


regulation of acetate catabolic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of acetate, the anion of acetic acid.


positive regulation of homocysteine metabolic process

Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving homocysteine.


negative regulation of homoserine biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of homoserine biosynthetic process.


positive regulation of fever generation by positive regulation of prostaglandin biosynthesis

Any process that increases the rate or extent of fever generation via positive regulation of the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin.


regulation of homoserine biosynthetic process

Any process that modulates the frequency, rate or extent of homoserine biosynthetic process.


positive regulation of ecdysteroid metabolic process

Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving ecdysteroids.


positive regulation of acetate catabolic process

Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of acetate.


negative regulation of gerfelin biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of gerfelin biosynthetic process.


positive regulation of tetrapyrrole biosynthetic process from glycine and succinyl-CoA

Any process that activates or increases the frequency, rate or extent of tetrapyrrole biosynthetic process from glycine and succinyl-CoA.


negative regulation of ecdysteroid metabolic process

Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving ecdysteroids.


regulation of fumonisin biosynthetic process

Any process that modulates the frequency, rate or extent of fumonisin biosynthetic process.


positive regulation of proline catabolic process to glutamate

Any process that activates or increases the frequency, rate or extent of proline catabolic process to glutamate.


regulation of penicillin catabolic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways leading to the breakdown of any antibiotic that contains the condensed beta-lactamthiazolidine ring system.


regulation of gibberellin biosynthetic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of gibberellins.


negative regulation of emericellin biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of emericellin biosynthetic process.


positive regulation of glyoxylate cycle

Any process that activates or increases the frequency, rate or extent of glyoxylate cycle.


regulation of retinoic acid biosynthetic process

Any process that modulates the frequency, rate or extent of retinoic acid biosynthetic process.


negative regulation of endocrocin biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of endocrocin biosynthetic process.


regulation of emericellin biosynthetic process

Any process that modulates the frequency, rate or extent of emericellin biosynthetic process.


negative regulation of cysteine metabolic process

Any process that stops, prevents or reduces the frequency, rate or extent of cysteine metabolic process.


positive regulation of cellular glucuronidation

Any process that activates or increases the frequency, rate or extent of cellular glucuronidation.


regulation of arginine biosynthetic process

Any process that modulates the frequency, rate or extent of arginine biosynthetic process.


positive regulation of retinoic acid biosynthetic process

Any process that activates or increases the frequency, rate or extent of retinoic acid biosynthetic process.


regulation of proline metabolic process

Any process that modulates the frequency, rate or extent of proline metabolic process.


negative regulation of asperthecin biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of asperthecin biosynthetic process.


negative regulation of kojic acid biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of kojic acid biosynthetic process.


regulation of tensidol B biosynthetic process

Any process that modulates the frequency, rate or extent of tensidol B biosynthetic process.


negative regulation of neosartoricin biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of neosartoricin biosynthetic process.


positive regulation of proline metabolic process

Any process that activates or increases the frequency, rate or extent of proline metabolic process.


regulation of fever generation by regulation of prostaglandin biosynthesis

Any process that modulates the rate or extent of fever generation via regulation of the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin.


negative regulation of arginine catabolic process

Any process that stops, prevents or reduces the frequency, rate or extent of arginine catabolic process.


regulation of selenocysteine metabolic process

Any process that modulates the frequency, rate or extent of selenocysteine metabolic process.


positive regulation of gibberellin biosynthetic process

Any process that activates, maintains or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of gibberellins.


positive regulation of glutamate metabolic process

Any process that activates or increases the frequency, rate or extent of glutamate metabolic process.


positive regulation of L-dopa biosynthetic process

Any process that activates or increases the frequency, rate or extent of L-dopa biosynthetic process.


positive regulation of ammonia assimilation cycle

Any process that activates or increases the frequency, rate or extent of ammonia assimilation cycle.


positive regulation of homoserine biosynthetic process

Any process that activates or increases the frequency, rate or extent of homoserine biosynthetic process.


positive regulation of arginine biosynthetic process

Any process that activates or increases the frequency, rate or extent of arginine biosynthetic process.


regulation of methane biosynthetic process from formic acid

Any process that modulates the frequency, rate or extent of methane biosynthetic process from formic acid.


initiation of acetate catabolic process

The activation of the chemical reactions and pathways resulting in the breakdown of acetate.


negative regulation of helvolic acid biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of helvolic acid biosynthetic process.


negative regulation of butyryl-CoA catabolic process to butyrate

Any process that stops, prevents or reduces the frequency, rate or extent of butyryl-CoA catabolic process to butyrate.


regulation of abscisic acid biosynthetic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of abscisic acid.


regulation of 1-aminocyclopropane-1-carboxylate metabolic process

Regulation of the chemical reactions and pathways involving 1-aminocyclopropane-1-carboxylate, the anion of 1-aminocyclopropane-1-carboxylic acid, a natural product found in plant tissues. It is a key intermediate in the biosynthesis of ethylene (ethene), a fruit-ripening hormone in plants.


positive regulation of selenocysteine metabolic process

Any process that activates or increases the frequency, rate or extent of selenocysteine metabolic process.


negative regulation of polyketide biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of polyketide biosynthetic process.


negative regulation of L-dopa biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of L-dopa biosynthetic process.


regulation of androst-4-ene-3,17-dione biosynthetic process

Any process that modulates the frequency, rate or extent of androst-4-ene-3,17-dione biosynthetic process.


positive regulation of lysine biosynthetic process via alpha-aminoadipate and saccharopine

Any process that activates or increases the frequency, rate or extent of lysine biosynthetic process via alpha-aminoadipate and saccharopine.


regulation of ammonia assimilation cycle

Any process that modulates the frequency, rate or extent of ammonia assimilation cycle.


regulation of tetrapyrrole biosynthetic process from glutamate

Any process that modulates the frequency, rate or extent of tetrapyrrole biosynthetic process from glutamate.


regulation of ecdysteroid biosynthetic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ecdysteroids.


positive regulation of gamma-aminobutyric acid catabolic process

Any process that activates or increases the frequency, rate or extent of gamma-aminobutyric acid catabolic process.


negative regulation of progesterone biosynthetic process

Any process that stops, prevents, or reduces the frequency, rate or extent of progesterone biosynthetic process.


negative regulation of penicillin metabolic process

Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving any antibiotic that contains the condensed beta-lactamthiazolidine ring system.


positive regulation of naphtho-gamma-pyrone biosynthetic process

Any process that activates or increases the frequency, rate or extent of naphtho-gamma-pyrone biosynthetic process.


negative regulation of glyoxylate cycle

Any process that stops, prevents or reduces the frequency, rate or extent of glyoxylate cycle.


negative regulation of methane biosynthetic process from formic acid

Any process that stops, prevents or reduces the frequency, rate or extent of methane biosynthetic process from formic acid.


negative regulation of 'de novo' NAD biosynthetic process from tryptophan

Any process that stops, prevents or reduces the frequency, rate or extent of 'de novo' NAD biosynthetic process from tryptophan.


negative regulation of proline biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of proline biosynthetic process.


regulation of xanthone-containing compound biosynthetic process

Any process that modulates the frequency, rate or extent of xanthone-containing compound biosynthetic process.


initiation of acetate catabolic process by acetate

The activation, by acetate, of the chemical reactions and pathways resulting in the breakdown of acetate.


positive regulation of fatty acid beta-oxidation by serotonin receptor signaling pathway

biolink:Pathway biolink:BiologicalProcess biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:OntologyClass biolink:Occurrent biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

A serotonin receptor signaling pathway that results in positive regulation of fatty acid beta-oxidation.


negative regulation of F-9775A biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of F-9775A biosynthetic process.


negative regulation of F-9775B biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of F-9775B biosynthetic process.


regulation of kojic acid biosynthetic process

Any process that modulates the frequency, rate or extent of kojic acid biosynthetic process.


regulation of o-orsellinic acid biosynthetic process

Any process that modulates the frequency, rate or extent of o-orsellinic acid biosynthetic process.


regulation of tetrapyrrole biosynthetic process from glycine and succinyl-CoA

Any process that modulates the frequency, rate or extent of tetrapyrrole biosynthetic process from glycine and succinyl-CoA.


regulation of penicillin metabolic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving any antibiotic that contains the condensed beta-lactamthiazolidine ring system.


negative regulation of proline metabolic process

Any process that stops, prevents, or reduces the frequency, rate or extent of proline metabolic process.


negative regulation of ecdysteroid biosynthetic process

Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ecdysteroids.


regulation of fatty acid beta-oxidation using acyl-CoA dehydrogenase

Any process that modulates the frequency, rate or extent of fatty acid beta-oxidation using acyl-CoA dehydrogenase.


positive regulation of 'de novo' NAD biosynthetic process from tryptophan

Any process that activates or increases the frequency, rate or extent of 'de novo' NAD biosynthetic process from tryptophan.


positive regulation of methane biosynthetic process from 3-(methylthio)propionic acid

Any process that activates or increases the frequency, rate or extent of methane biosynthetic process from 3-(methylthio)propionic acid.


regulation of jasmonic acid metabolic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving jasmonic acid.


regulation of leucine biosynthetic process

Any process that modulates the frequency, rate or extent of leucine biosynthetic process.


negative regulation of progesterone biosynthesis involved in luteolysis

Any process that decreases the rate, frequency or extent of the biosynthesis of progesterone biosynthesis that contributes to luteolysis.


positive regulation of xanthone-containing compound biosynthetic process

Any process that activates or increases the frequency, rate or extent of xanthone-containing compound biosynthetic process.


regulation of L-ascorbic acid biosynthetic process

Any process that modulates the frequency, rate or extent of L-ascorbic acid biosynthetic process.


regulation of neosartoricin biosynthetic process

Any process that modulates the frequency, rate or extent of neosartoricin biosynthetic process.


negative regulation of o-orsellinic acid biosynthetic process

Any process that stops, prevents or reduces the frequency, rate or extent of o-orsellinic acid biosynthetic process.


regulation of monodictyphenone biosynthetic process

Any process that modulates the frequency, rate or extent of monodictyphenone biosynthetic process.


positive regulation of tetrapyrrole biosynthetic process from glutamate

Any process that activates or increases the frequency, rate or extent of tetrapyrrole biosynthetic process from glutamate.


positive regulation of butyryl-CoA catabolic process to butyrate

Any process that activates or increases the frequency, rate or extent of butyryl-CoA catabolic process to butyrate.


positive regulation of citrulline biosynthetic process

Any process that activates or increases the frequency, rate or extent of citrulline biosynthetic process.


regulation of indoleacetic acid biosynthetic process via tryptophan

Any process that modulates the frequency, rate or extent of indoleacetic acid biosynthetic process via tryptophan.


cobyrinic acid a,c-diamide synthase activity

Catalysis of the conversion of cobyrinic acid to cobyrinic acid a,c-diamide via the intermediate formation of cobyrinic acid c-monoamide.


Anal Intraepithelial Neoplasia 2

Anal canal or perianal skin intraepithelial neoplasia with moderate dysplasia.


temporal lobe cancer

A cancer that involves the temporal lobe.


neoplasm of temporal lobe

A neoplasm (disease) that involves the temporal lobe.


Metastatic malignant neoplasm to vertebral column

The spread of a malignant neoplasm to the spine.  This may be from a primary spinal malignant neoplasm, or from a malignant neoplasm at a distant site.


Prostate Carcinoma Metastatic in the Bone

A carcinoma that arises from the prostate gland and has spread to the bone.